Factors influencing serum aluminum in CAPD patients.
The aim of this study was to find out the relationship between body iron stores and serum aluminum levels among 82 stable CAPD patients. The influence of other factors such as time on CAPD and residual renal function was also considered. Thirty-three patients received aluminum hydroxide as a phosphate binder, and they had significantly higher aluminum levels (36.45 microg/l) than the patients who were not taking aluminum preparations (17.2 microg/l, p = 0.001). A statistically-significant correlation between serum aluminum levels and residual renal function and time on CAPD was also observed (p <0.05). However, there was no relationship between serum aluminum levels and serum iron, ferritin and transferrin saturation, neither between body iron stores and total excretion of aluminum (p >0.05). In previous reports, low serum iron levels were associated with high serum aluminum concentration among hemodialysis patients. However, this effect was not observed in the CAPD population under study. The highest risk of hyperaluminemia was found in the patients who were taking aluminum hydroxide, had worse residual renal function and had been longer on CAPD.
Montenegro
J
J
Servicio de Nefrología, Hospital de Galdácano, Spain.
Aguirre
R
R
Saracho
R
R
Moina
I
I
Martínez
I
I
D000535:Aluminum / Q000097:blood*; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000097:blood; D007668:Kidney / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D013997:Time Factors; D014168:Transferrin / Q000032:analysis
D014168:Transferrin; D000536:Aluminum Hydroxide; D005293:Ferritins; D000535:Aluminum; D007501:Iron